Company release
09.00 Finnish time / 08.00 Swedish time
The shares of
Effective
For further information, please contact:
peter.hanninen@nanoform.com, +358 50 353 0408
For investor relations queries, please contact:
hvh@nanoform.com, +46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and
https://news.cision.com/nanoform/r/nanoform-finland-plc--certified-adviser-change-to-carnegie-investment-bank-ab,c3957549
https://mb.cision.com/Main/18905/3957549/2714971.pdf
(c) 2024 Cision. All rights reserved., source